drugset / Trial / NCT06956261
NW-301 TCR-T in Patients With Advanced Solid Tumor
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor
Timeline
- Start
- 2025-05-10
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NW-301D | Cell therapy | — | — |
| Subject | NW-301V | Cell therapy | — | — |